A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts
Open Access
- 23 February 2021
- Vol. 10 (2), 480
- https://doi.org/10.3390/cells10020480
Abstract
Mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal-dominant Parkinson’s disease (PD) and contribute to sporadic PD. Common genetic variation in LRRK2 modifies susceptibility to immunological disorders including Crohn’s disease and leprosy. Previous studies have reported that LRRK2 is expressed in B lymphocytes and macrophages, suggesting a role for LRRK2 in immunological functions. In this study, we characterized the LRRK2 protein expression and phosphorylation using human lymphoblasts. Lipopolysaccharide (LPS), a proinflammatory agent, induced the increase of LRRK2 expression and kinase activities in human lymphoblasts in a time-dependent manner. Moreover, LPS activated the Toll-like receptor (TLR) signaling pathway, increased TRAF6/LRRK2 interaction, and elevated the phosphorylation levels of MAPK (JNK1/2, p38, and ERK1/2) and IkBα. Treatment with LRRK2 inhibitor 68 reduced LPS-induced TRAF6/LRRK2 interaction and MAPK and IkBα phosphorylation, thereby reducing TNF-α secretion. These results indicate that LRRK2 is actively involved in proinflammatory responses in human lymphoblasts, and inhibition of GTP binding by 68 results in an anti-inflammation effect against proinflammatory stimuli. These findings not only provide novel insights into the mechanisms of LRRK2-linked immune and inflammatory responses in B-cell-like lymphoblasts, but also suggest that 68 may also have potential therapeutic value for LRRK2-linked immunological disorders.Funding Information
- National Institutes of Health, USA (R01NS093383; R21NS096620)
This publication has 53 references indexed in Scilit:
- LRRK2 kinase activity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: Suppression by curcuminNeurobiology of Disease, 2012
- The IkappaB Kinase Family Phosphorylates the Parkinson's Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor SignalingPLOS ONE, 2012
- LRRK2 Inhibition Attenuates Microglial Inflammatory ResponsesJournal of Neuroscience, 2012
- LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1Human Molecular Genetics, 2012
- Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2Nature Chemical Biology, 2011
- Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility lociNature Genetics, 2010
- LRRK2 Is Involved in the IFN-γ Response and Host Response to PathogensThe Journal of Immunology, 2010
- Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's diseaseNature Medicine, 2010
- Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's diseaseNature Genetics, 2008
- Production of TNFα by LPS-stimulated murine, rat and human blood and its pharmacological modulationInflammation Research, 1993